PMID- 25007068 OWN - NLM STAT- MEDLINE DCOM- 20150410 LR - 20220316 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 15 IP - 7 DP - 2014 Jul 8 TI - Cordycepin inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-alpha production via activating amp-activated protein kinase (AMPK) signaling. PG - 12119-34 LID - 10.3390/ijms150712119 [doi] AB - Tumor necrosis factor (TNF)-alpha is elevated during the acute phase of Kawasaki disease (KD), which damages vascular endothelial cells to cause systemic vasculitis. In the current study, we investigated the potential role of cordycepin on TNFalpha expression in both lipopolysaccharide (LPS)-stimulated macrophages and ex vivo cultured peripheral blood mononuclear cells (PBMCs) of KD patients. We found that cordycepin significantly suppressed LPS-induced TNFalpha expression and production in mouse macrophages (RAW 264.7 cells and bone marrow-derived macrophages (BMDMs)). Meanwhile, cordycepin alleviated TNFalpha production in KD patients' PBMCs. PBMCs from healthy controls had a much lower level of basal TNF-alpha content than that of KD patients. LPS-induced TNF-alpha production in healthy controls' PBMCs was also inhibited by cordycepin. For the mechanism study, we discovered that cordycepin activated AMP-activated protein kinase (AMPK) signaling in both KD patients' PBMCs and LPS-stimulated macrophages, which mediated cordycepin-induced inhibition against TNFalpha production. AMPK inhibition by its inhibitor (compound C) or by siRNA depletion alleviated cordycepin's effect on TNFalpha production. Further, we found that cordycepin inhibited reactive oxygen species (ROS) production and nuclear factor kappa B (NF-kappaB) activation in LPS-stimulate RAW 264.7 cells or healthy controls' PBMCs. PBMCs of KD patients showed higher basal level of ROS and NF-kappaB activation, which was also inhibited by cordycepin co-treatment. In conclusion, our data showed that cordycepin inhibited TNFalpha production, which was associated with AMPK activation as well as ROS and NF-kappaB inhibition. The results of this study should have significant translational relevance in managing this devastating disease. FAU - Zhang, Jian-Li AU - Zhang JL AD - Department of Respiration, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, China. jianlizhangjj@163.com. FAU - Xu, Ying AU - Xu Y AD - Department of Pediatrics, the First People's Hospital of Hangzhou, Hangzhou 310003, China. yingyingxuxu163@163.com. FAU - Shen, Jie AU - Shen J AD - Department of Pediatrics, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, China. drchunlinwang@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140708 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Antineoplastic Agents) RN - 0 (Deoxyadenosines) RN - 0 (Lipopolysaccharides) RN - 0 (Tumor Necrosis Factor-alpha) RN - EC 2.7.11.31 (AMP-Activated Protein Kinases) RN - GZ8VF4M2J8 (cordycepin) SB - IM MH - AMP-Activated Protein Kinases/*metabolism MH - Animals MH - Antineoplastic Agents/*pharmacology MH - Case-Control Studies MH - Cell Culture Techniques MH - Cells, Cultured MH - Deoxyadenosines/*pharmacology MH - Humans MH - Lipopolysaccharides/pharmacology MH - Macrophages/drug effects/*metabolism MH - Mice MH - Mucocutaneous Lymph Node Syndrome/*metabolism MH - Signal Transduction MH - Tumor Necrosis Factor-alpha/*metabolism PMC - PMC4139833 EDAT- 2014/07/10 06:00 MHDA- 2015/04/11 06:00 PMCR- 2014/07/01 CRDT- 2014/07/10 06:00 PHST- 2014/04/19 00:00 [received] PHST- 2014/06/06 00:00 [revised] PHST- 2014/06/18 00:00 [accepted] PHST- 2014/07/10 06:00 [entrez] PHST- 2014/07/10 06:00 [pubmed] PHST- 2015/04/11 06:00 [medline] PHST- 2014/07/01 00:00 [pmc-release] AID - ijms150712119 [pii] AID - ijms-15-12119 [pii] AID - 10.3390/ijms150712119 [doi] PST - epublish SO - Int J Mol Sci. 2014 Jul 8;15(7):12119-34. doi: 10.3390/ijms150712119.